Disc Medicine (IRON) Return on Capital Employed (2020 - 2026)
Disc Medicine's (IRON) quarterly Return on Capital Employed came in at 35.54% in Q1 2026, down 1188.0% year-on-year from 3.27% in Q1 2025, and down 2.69% on a QoQ basis from 34.61% in Q4 2025.
Disc Medicine (IRON) Return on Capital Employed (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Return on Capital Employed data on file, last reported at 35.54% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1188.0% year-over-year to 35.54% in Q1 2026; TTM through Mar 2026 was 35.54%, a 1188.0% decrease from a year earlier, with the FY2025 full-year figure at 38.37%, down 665.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 35.54%, down from 34.61% in the prior quarter.
- Over the last five years, Return on Capital Employed for IRON reached as high as 11.21% in Q3 2022 and fell as low as 36.37% in Q4 2022.
- Historically, Return on Capital Employed has averaged 26.49% across 5 years, with a median of 26.17% in 2024.
- Across the five-year window, Return on Capital Employed surged 2321 bps in 2022 and sank 1188 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 36.37% in 2022, then advanced by 29 bps to 25.98% in 2023, then slipped by 6 bps to 27.45% in 2024, then decreased by 26 bps to 34.61% in 2025, then decreased by 3 bps to 35.54% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 35.54% in Q1 2026, 34.61% in Q4 2025, and 32.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Disc Medicine | 2.90 Bn | 2.90 Bn | - | -35.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.54% |
| Dec 31, 2025 | -34.61% |
| Sep 30, 2025 | -32.79% |
| Jun 30, 2025 | -25.32% |
| Mar 31, 2025 | -23.65% |
| Dec 31, 2024 | -27.45% |
| Sep 30, 2024 | -26.17% |
| Jun 30, 2024 | -26.95% |
| Mar 31, 2024 | -28.15% |
| Dec 31, 2023 | -25.98% |
| Sep 30, 2023 | -20.89% |
| Jun 30, 2023 | -22.33% |
| Mar 31, 2023 | -29.55% |
| Dec 31, 2022 | -36.37% |
| Sep 30, 2022 | -11.21% |
| Jun 30, 2022 | -17.89% |
| Mar 31, 2022 | -25.51% |
| Dec 31, 2021 | -27.98% |
| Sep 30, 2021 | -34.42% |
| Jun 30, 2021 | -24.54% |